With respect to the PI3K/AKT/mTOR pathway, the dual PI3K/mTOR inhibitor dactolisib attenuated tumor progression in animal models of glioma [6,7], and the allosteric AKT inhibitor MK-2206 presented antitumoral effects in vitro [8,9]. The gene discussed is AKT1; the disease is central nervous system cancer.